HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Predictive Genes for the Prognosis of Central Serous Chorioretinopathy.

AbstractPURPOSE:
To investigate potential genetic prognostic factors associated with spontaneous resolution of serous retinal detachment (SRD) and development of choroidal neovascularization (CNV) in central serous chorioretinopathy (CSC).
DESIGN:
Retrospective analysis of a case series.
PARTICIPANTS:
One hundred ninety-six eyes from 196 patients with active CSC.
METHODS:
We retrospectively reviewed medical records and determined the presence or absence of SRD using OCT imaging. The duration until the spontaneous SRD resolution was analyzed using the Kaplan-Meier method, and associations between the duration to spontaneous resolution and Complement factor H (CFH) I62V, Age-Related Maculopathy Susceptibility 2 (ARMS2) A69S, or Vasoactive Intestinal Peptide Receptor 2 (VIPR2) rs3793217 genotypes were evaluated, followed by the assessment of their associations with CNV that developed secondary to CSC.
MAIN OUTCOME MEASURES:
Genetic associations of CFH rs800292, ARMS2 rs10490924, and VIPR2 rs3793217 genotypes with the duration to spontaneous resolution of SRD and development of CNV during follow-up of CSC.
RESULTS:
In 105 of the 196 study participants, we revealed spontaneous SRD resolution in their eyes during follow-up evaluation. Sixty-eight eyes received treatment, and 23 eyes dropped out before spontaneous SRD resolution. Among the 3 genetic polymorphisms assessed herein, only the CFH I62V genotype was predictive of spontaneous SRD resolution among its genotypes (P = 0.017); the average durations for the spontaneous SRD resolution for the individuals with AA, AG, and GG genotype were 126.6±115.5 days, 157.7±243.1 days, and 242.7±198.0 days, respectively, indicating that the G allele was associated with significantly longer persistent SRD (P = 0.035). Among the total number of eyes of all participants, 14 demonstrated CNV during follow-up evaluation. The CFH I62V G and ARMS2 A69S T alleles were associated significantly with CNV development (P = 0.0023 and P = 0.019, respectively), whereas the VIPR2 rs3793217 genotype was not.
CONCLUSIONS:
The CFH I62V and ARMS2 A69S genotypes can predict the prognosis of CSC. Knowledge of the genetic status may help physicians determine the need for early treatment and possibly prevent subsequent CNV development. Further prospective studies are needed to confirm the observed genotype-phenotype relationship.
AuthorsYoshikatsu Hosoda, Kenji Yamashiro, Masahiro Miyake, Sotaro Ooto, Akio Oishi, Manabu Miyata, Akihito Uji, Chiea Chuen Khor, Tien Yin Wong, Akitaka Tsujikawa
JournalOphthalmology. Retina (Ophthalmol Retina) Vol. 3 Issue 11 Pg. 985-992 (11 2019) ISSN: 2468-6530 [Electronic] United States
PMID31331787 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Chemical References
  • ARMS2 protein, human
  • CFH protein, human
  • Coloring Agents
  • Proteins
  • Receptors, Vasoactive Intestinal Peptide, Type II
  • VIPR2 protein, human
  • Complement Factor H
  • Indocyanine Green
Topics
  • Adult
  • Central Serous Chorioretinopathy (diagnosis, genetics, physiopathology)
  • Choroidal Neovascularization (diagnosis)
  • Coloring Agents (administration & dosage)
  • Complement Factor H (genetics)
  • Female
  • Fluorescein Angiography
  • Genotype
  • Humans
  • Indocyanine Green (administration & dosage)
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • Prognosis
  • Proteins (genetics)
  • Receptors, Vasoactive Intestinal Peptide, Type II (genetics)
  • Retinal Detachment (physiopathology)
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: